Plain-English translation of NCT07216404 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is studying whether — a naturally occurring psychedelic compound — combined with professional counseling can help reduce depression in people living with non-small cell lung cancer. The study will look at whether this medication is safe to use, whether patients find it acceptable, and whether it actually helps ease depression, worry, and existential concerns that often come with a cancer diagnosis.
People with lung cancer often experience significant depression and anxiety related to their diagnosis, but current treatments don't always work well or feel right for everyone. Researchers believe this medication, paired with therapy, may offer a new way to help people cope with the emotional weight of cancer.
You likely qualify if…
You likely don't qualify if…
You would attend two four-hour counseling sessions about a week apart to prepare, then take the medication in a single supervised session lasting 8–10 hours on day 21. After that, you would have two more two-hour therapy sessions to help process the experience. The study also involves blood and urine tests at various points. You would be followed up at 4 weeks and 12 weeks after the medication session to see how you're doing.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States